Lamivudine/interferon combination therapy prevents the appearance of YMDD mutants in anti-HBE positive chronic hepatitis B: A controlled pilot study
Massimo Levrero(Northwest Medical Specialties), Clara Balsano(University of L'Aquila), Giancarlo Iaiani(Policlinico Umberto I), M.E. Bonaventura, R. Paffetti, I. A. Gallo, Angelo Rossini(Centro Universitário Barão de Mauá), F Soccorsi, G. Bombardieri, Gilda Stivali(Fondazione Andrea Cesalpino)
Cited by 0
Related Papers
Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure
|Gut|2015|273
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Bridging the “last mile” gap between AI implementation and operation: “data awareness” that matters
|Annals of Translational Medicine|2020|109
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study
|The American Journal of Gastroenterology|2002|80